drugset
drugset / Trial / NCT05274802

A Study of ALS-4 in Healthy Adults Subjects

NCT05274802 ↗

Phase 1 Completed 72 enrolled Aptorum International Limited
RandomizedSequentialTriple-blindTreatment

Summary

A Phase I trial to evaluate the safety, tolerability and Pharmacokinetics of ALS-4 (IM032) in a single ascending dose (SAD) and multiple ascending dose (MAD) in healthy adult subjects.

Timeline

Start
2021-03-20
Primary completion
2021-12-22
Completion
2022-01-02

Drugs

EvaluationDrugModalityDoseRoute
Subject ALS-4 Unknown 25 mg Oral
Subject ALS-4 Unknown 50 mg Oral
Subject ALS-4 Unknown 100 mg Oral
Subject ALS-4 Unknown 200 mg Oral
Subject ALS-4 Unknown 300 mg Oral

Indications

No indication recorded.